Genentech
In Brief This Week: PerkinElmer, Chembio, Becton Dickinson, Fulgent Genetics, and More
News items for the in vitro diagnostic industry for the week of Sept. 20, 2021.
Oncocyte AACR Data Expands Potential Applications for Immunotherapy Response Predictor
The firm presented evidence that its DetermaIO gene expression test can help predict which bladder cancer patients are likely to respond to immune checkpoint inhibitors.
Invitae, Pharma Firms Partner to Develop Standard MRD Panel for AML Clinical Trials
Invitae is working with Bristol Myers Squibb, Janssen, Novartis, and Genentech to advance an NGS panel to gauge the efficacy of AML treatments in trials.
Adaptive Biotechnologies Prepares to Launch T Cell-Based COVID-19 Test
Adaptive is rebranding its immunoSeq Dx assay as T-Detect and plans to submit for an EUA for a COVID-19 T-Cell response test by the end of the year.
Roche EGFR Mutation Test Approved by FDA as Companion Diagnostic for NSCLC
Roche's real-time PCR test detects defined mutations of the epidermal growth factor receptor gene in DNA from non-small cell lung cancer patients.